PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway

General Physiology and Biophysics · Published 2026-01-01 · DOI 10.4149/gpb_2025043

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.4149/gpb_2025043

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles